IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 224 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,322,500 | -27.8% | 950,000 | +11.8% | 0.47% | -26.1% |
| Q2 2023 | $5,984,000 | +41.8% | 850,000 | +23.9% | 0.63% | +36.3% |
| Q1 2023 | $4,219,946 | -23.6% | 686,170 | -20.6% | 0.46% | -19.6% |
| Q4 2022 | $5,523,375 | +16.0% | 864,378 | +69.5% | 0.58% | +15.4% |
| Q3 2022 | $4,763,000 | -18.6% | 510,000 | -3.8% | 0.50% | -25.0% |
| Q2 2022 | $5,851,000 | -26.0% | 530,000 | +11.6% | 0.66% | -14.7% |
| Q1 2022 | $7,909,000 | -32.1% | 475,000 | -20.8% | 0.78% | +0.6% |
| Q4 2021 | $11,652,000 | +47.7% | 600,000 | +87.5% | 0.78% | +39.9% |
| Q3 2021 | $7,891,000 | +1.1% | 320,000 | +6.7% | 0.55% | +4.5% |
| Q2 2021 | $7,806,000 | -16.4% | 300,000 | +1.7% | 0.53% | -18.6% |
| Q1 2021 | $9,340,000 | -37.1% | 295,000 | -7.8% | 0.65% | -46.2% |
| Q4 2020 | $14,848,000 | +32.7% | 320,000 | -5.9% | 1.21% | +21.7% |
| Q3 2020 | $11,193,000 | +19.9% | 340,000 | 0.0% | 1.00% | -1.3% |
| Q2 2020 | $9,333,000 | -14.6% | 340,000 | -6.8% | 1.01% | -34.2% |
| Q1 2020 | $10,926,000 | -16.9% | 365,000 | -23.2% | 1.53% | +6.2% |
| Q4 2019 | $13,148,000 | +38.9% | 475,000 | -8.7% | 1.44% | +21.5% |
| Q3 2019 | $9,464,000 | -48.6% | 520,000 | -30.7% | 1.19% | -41.5% |
| Q2 2019 | $18,407,000 | +120.0% | 750,700 | -14.7% | 2.03% | +107.4% |
| Q1 2019 | $8,365,000 | -21.6% | 879,600 | -27.0% | 0.98% | -19.8% |
| Q4 2018 | $10,669,000 | -26.5% | 1,205,495 | -6.6% | 1.22% | -16.2% |
| Q3 2018 | $14,518,000 | +33.8% | 1,290,495 | +52.3% | 1.46% | +31.1% |
| Q2 2018 | $10,848,000 | -32.0% | 847,476 | -10.2% | 1.11% | -43.6% |
| Q1 2018 | $15,957,000 | +111.3% | 944,185 | 0.0% | 1.97% | +92.7% |
| Q4 2017 | $7,553,000 | +37.0% | 944,185 | +32.8% | 1.02% | +45.0% |
| Q3 2017 | $5,512,000 | +15.4% | 711,163 | +9.4% | 0.70% | +2.6% |
| Q2 2017 | $4,778,000 | – | 650,000 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |